Drug Trial Radar · NCT05890729
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 10, 2023
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Xentria, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
Conditions
- Pulmonary Sarcoidosis
Interventions
XTMAB-16 or PlaceboDrug
Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study durationTime frame: Throughout Study Duration, 20 weeks
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Xentria Investigative Site
Birmingham, Alabama
Xentria Investigative Site
Denver, Colorado
Xentria Investigative Site
Jacksonville, Florida
Xentria Investigative Site
Chicago, Illinois
Xentria Investigative Site
Chicago, Illinois
Xentria Investigative Site
Iowa City, Iowa
Xentria Investigative Site
Baltimore, Maryland
Xentria Investigative Site
Detroit, Michigan
Xentria Investigative Site
Minneapolis, Minnesota
Xentria Investigative Site
Albany, New York
Xentria Investigative Site
New York, New York
Xentria Investigative Site
Greenville, North Carolina
Xentria Investigative Site
Cincinnati, Ohio
Xentria Investigative Site
Philadelphia, Pennsylvania
Xentria Investigative Site
Charleston, South Carolina
Xentria Investigative Site
Charlottesville, Virginia
Xentria Investigative Site
Prague, Czechia
Xentria Investigative Site
Aalborg, Denmark
Xentria Investigative Site
Aarhus, Denmark
Xentria Investigative Site
Odense, Denmark
Xentria Investigative Site
Roskilde, Denmark
Xentria Investigative Site
Vejle, Denmark
Xentria Investigative Site
Bielsk Podlaski, Poland
Xentria Investigative Site
Lodz, Poland
Xentria Investigative Site
Barcelona, Spain
Xentria Investigative Site
Barcelona, Spain
Xentria Investigative Site
Seville, Spain
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, England, United Kingdom
University College London Hospitals NHS Foundation Trust
London, England, United Kingdom
King's College Hospital NHS Foundation Trust
London, England, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, England, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, England, United Kingdom
NHS Tayside
Perth, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.